PDF(Pubmed)
Abstract：
This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization\'s endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries.
摘要：
本评论描述了在第23份世卫组织基本药物标准清单中纳入息肉对预防心血管疾病的潜在影响，并提供了采用的路线图，实施，维持,和扩大规模。世界卫生组织对polypills的认可对于改善全球获取至关重要，特别是在低收入和中等收入国家。与患有普遍心血管疾病的人群相比，一级预防人群的致命性和非致命性心血管疾病负担明显较高，预计健康收益最大。注重收养，实施，维持,需要扩大用于预防心血管疾病的息肉病，包括增加现有息肉病的供应，并将息肉病纳入世界卫生组织HEARTS技术包，以纳入初级保健系统，以实现对人口健康的这些益处。广泛实施预防心血管疾病的息肉疗法有可能通过简化治疗方案和扩大经济层面的可及性，公平地减少全球心血管疾病的影响。国家和国家内部。
